49743-87-5

Usage

Uses

Used in Organic Synthesis:
4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID is used as a key intermediate for the synthesis of various organic compounds. Its unique structure allows for further functionalization and modification, leading to the creation of new molecules with diverse properties and applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID is utilized as a starting material for the development of new drugs. Its structural properties make it a valuable component in the design and synthesis of pharmaceuticals with potential therapeutic effects.
Used in the Synthesis of Complex Organic Compounds:
4'-HYDROXYMETHYL-BIPHENYL-4-CARBOXYLIC ACID serves as a building block in the synthesis of complex organic compounds. Its presence in these compounds can contribute to the development of materials with unique properties and functions, such as advanced polymers, specialty chemicals, and other high-value products.

Upstream product

• 873-75-6 4-bromobenzenemethanol 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 792-74-5 4,4'-biphenyldicarboxylic acid dimethyl ester 
• 393522-78-6 methyl 4'-(hydroxymethyl)-[1,1'-biphenyl]-4-carboxylate 

Downstream Products

• 1258270-24-4 C₃₂H₃₃NO₄ 
• 393522-73-1 [4'-(4-hydroxymethyl-phenylcarbamoyloxymethyl)-biphenyl-4-yl]-carbamic acid allyl ester 
• 393522-92-4 (4'-benzylcarbamoyloxymethyl-biphenyl-4-yl)-carbamic acid allyl ester 
• 393522-89-9 (4'-hydroxymethyl-biphenyl-4-yl)-carbamic acid allyl ester 

Relevant academic research and scientific papers

Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR

The Bcl-2 family of proteins plays a major role in the regulation of apoptosis, or programmed cell death. Overexpression of the anti-apoptotic members of this family (Bcl-2, Bcl-xL, and Mcl-1) can render cancer cells resistant to chemotherapeutic agents and therefore these proteins are important targets for the development of new anti-cancer agents. Here we describe the discovery of a potent, highly selective, Bcl-2 inhibitor using SAR by NMR and structure-based drug design which could serve as a starting point for the development of a Bcl-2 selective anti-cancer agent. Such an agent would potentially overcome the Bcl-xL mediated thrombocytopenia observed with ABT-263.

Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release

The design and synthesis of several novel elongated self-elimination spacer systems for application in prodrugs is described. These elongated spacer systems can be incorporated between a cleavable specifier and the parent drug. Naphthalene- and biphenyl-containing spacers were synthesized but did not eliminate. Prodrugs of the anticancer agents doxorubicin and paclitaxel are reported that contain two or three electronic cascade spacers. A novel catalytic application of HOBt was found for the synthesis of N-aryl carbamates through reacting a 4-nitrophenyl carbonate with an aniline derivative, to connect the 1,6-elimination spacers via a carbamate linkage. In addition, a double spacer-containing paclitaxel prodrug was synthesized, comprising a 1,6-elimination spacer and a bis-amine linker connected to paclitaxel via a 2′-carbamate linkage. Prodrugs in which the novel spacer systems were incorporated between a specific tripeptide specifier and the parent drug doxorubicin or paclitaxel proved to be significantly faster activated by plasmin in comparison with prodrugs containing conventional spacer systems. It is expected that the generally applicable novel spacer systems reported herein will contribute to future development of improved enzymatically activated prodrugs.